CIK 0001861560
NUVL Nuvalent, Inc.
Insider trading from SEC Form 4. Last filing Jul 17, 2026. Close $123.96 on Jul 14, 2026, 0% from the 52-week low and 0% from the high.
In brief
Nuvalent, Inc. (NUVL) has 126 SEC Form 4 filings on file from 16 insiders, the latest filed on Jul 17, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
84 open-market trades have been scored at NUVL. The newest: Henry E. Pelish (Chief Scientific Officer) sold $261k of stock on Jul 9, 2026, filed Jul 10, 2026, scored 23 (weak), under a 10b5-1 plan. The largest of the 50 shown: James E Flynn (director and 10% owner) sold $71M on Nov 24, 2025, scored 55 (moderate). 4 insiders sold within 14 days of each other around Jul 9, 2026.
25 Form 144 notices of planned sales are on file, the latest filed Jul 9, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
16
with a Form 4 at this company
Signals
Open-market buys and sells at Nuvalent, Inc., scored: the newest 50 of 84.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Henry E. Pelish Chief Scientific Officer sell | $261k 2,111 shares | -3% | - | |
| 30Weak | James Richard Porter President and CEO sell | $3.7M 30,000 shares | -8% | - | |
| 32Weak | Alexandra Balcom Chief Financial Officer sell | $1.4M 11,430 shares | -12% | - | |
| 30Weak | Darlene Noci Chief Development Officer sell | $2.8M 23,000 shares | -28% | - | |
| 16Weak | Darlene Noci Chief Development Officer sell | $679k 5,500 shares | -9% | - | |
| 30Weak | Darlene Noci Chief Development Officer sell | $2.5M 20,000 shares | -26% | - | |
| 30Weak | James Richard Porter President and CEO sell | $2.7M 30,000 shares | -8% | - | |
| 32Weak | Alexandra Balcom Chief Financial Officer sell | $1.1M 11,430 shares | -12% | - | |
| 14Weak | Deborah Ann Miller Chief Legal Officer sell | $593k 5,500 shares | -8% | - | |
| 14Weak | Darlene Noci Chief Development Officer sell | $593k 5,500 shares | -9% | - | |
| 30Weak | James Richard Porter President and CEO sell | $3.1M 30,000 shares | -8% | - | |
| 32Weak | Alexandra Balcom Chief Financial Officer sell | $1.1M 11,430 shares | -12% | - | |
| 14Weak | Deborah Ann Miller Chief Legal Officer sell | $546k 5,500 shares | -8% | - | |
| 14Weak | Darlene Noci Chief Development Officer sell | $548k 5,500 shares | -9% | - | |
| 9Weak | Henry E. Pelish Chief Scientific Officer sell | $323k 3,093 shares | -5% | - | |
| 30Weak | James Richard Porter President and CEO sell | $3.1M 30,000 shares | -8% | - | |
| 32Weak | Alexandra Balcom Chief Financial Officer sell | $1.2M 11,430 shares | -12% | - | |
| 14Weak | Darlene Noci Chief Development Officer sell | $538k 5,500 shares | -9% | - | |
| 14Weak | Deborah Ann Miller Chief Legal Officer sell | $543k 5,500 shares | -8% | - | |
| 32Weak | Alexandra Balcom Chief Financial Officer sell | $2.5M 25,130 shares | -23% | - | |
| 30Weak | Henry E. Pelish Chief Scientific Officer sell | $3.4M 35,104 shares | -35% | - | |
| 30Weak | James Richard Porter President and CEO sell | $3.0M 30,000 shares | -8% | - | |
| 14Weak | Deborah Ann Miller Chief Legal Officer sell | $567k 5,500 shares | -8% | - | |
| 14Weak | Darlene Noci Chief Development Officer sell | $567k 5,500 shares | -9% | - | |
| 7Weak | Darlene Noci Chief Development Officer sell | $561k 5,500 shares | -9% | - | |
| 18Weak | Deborah Ann Miller Chief Legal Officer sell | $1.7M 15,000 shares | -25% | - | |
| 38Weak | Alexandra Balcom Chief Financial Officer sell | $721k 7,417 shares | -8% | - | |
| 35Weak | Deborah Ann Miller Chief Legal Officer sell | $676k 6,952 shares | -14% | - | |
| 36Weak | Darlene Noci Chief Development Officer sell | $721k 7,417 shares | -15% | - | |
| 45Moderate | James Richard Porter President and CEO sell | $2.7M 27,433 shares | -9% | - | |
| 36Weak | Christopher Durant Turner Chief Medical Officer sell | $721k 7,417 shares | -12% | - | |
| 28Weak | Henry E. Pelish Chief Scientific Officer sell | $502k 5,160 shares | -7% | - | |
| 25Weak | Deborah Ann Miller Chief Legal Officer sell | $1.0M 10,000 shares | -17% | - | |
| 11Weak | Darlene Noci Chief Development Officer sell | $400k 4,000 shares | -8% | - | |
| 44Moderate | Alexandra Balcom Chief Financial Officer sell | $782k 7,084 shares | -11% | - | |
| 12Weak | Darlene Noci Chief Development Officer sell | $434k 4,000 shares | -8% | - | |
| 32Weak | Matthew Shair director sell | $820k 7,500 shares | -1% | - | |
| 55Moderate | James E Flynn director, owner, other sell | $71M 742,574 shares | -9% | - | |
| 37Weak | Alexandra Balcom Chief Financial Officer sell | $2.1M 20,729 shares | -25% | - | |
| 30Weak | Deborah Ann Miller Chief Legal Officer sell | $2.6M 24,200 shares | -33% | - | |
| 30Weak | Deborah Ann Miller Chief Legal Officer sell | $2.2M 21,800 shares | -31% | - | |
| 11Weak | Darlene Noci Chief Development Officer sell | $412k 4,000 shares | -8% | - | |
| 35Weak | Matthew Shair director sell | $6.0M 60,000 shares | -4% | - | |
| 12Weak | Deborah Ann Miller Chief Legal Officer sell | $475k 5,000 shares | -9% | - | |
| 13Weak | Alexandra Balcom Chief Financial Officer sell | $144k 1,683 shares | -3% | - | |
| 30Weak | Deborah Ann Miller Chief Legal Officer sell | $2.5M 28,000 shares | -43% | - | |
| 25Weak | Henry E. Pelish Chief Scientific Officer sell | $1.3M 14,205 shares | -18% | - | |
| 30Weak | James Richard Porter President and CEO sell | $2.4M 27,000 shares | -10% | - | |
| 37Weak | Alexandra Balcom Chief Financial Officer sell | $3.5M 40,000 shares | -49% | - | |
| 24Weak | Henry E. Pelish Chief Scientific Officer sell | $895k 10,070 shares | -14% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 9, 2026 | Henry E. Pelish Officer | 2,111 0.00% of outstanding | $261k | Jul 9, 2026 | $323k |
| Jul 1, 2026 | Alexandra Balcom Officer | 22,860 0.03% of outstanding | $2.8M | Jul 1, 2026 | $5.9M |
| Jun 9, 2026 | Darlene Noci Officer | 48,500 0.07% of outstanding | $6.0M | Jun 9, 2026 | $1.7M |
| Jun 8, 2026 | James Richard Porter Officer | 90,000 0.12% of outstanding | $8.1M | Jun 8, 2026 | $6.2M |
| Apr 30, 2026 | DEBORAH MILLER Officer | 16,500 0.02% of outstanding | $1.6M | Apr 30, 2026 | $1.1M |
| Mar 30, 2026 | Darlene Noci Officer | 22,000 0.03% of outstanding | $2.1M | Mar 30, 2026 | $1.5M |
| Mar 24, 2026 | Alexandra Balcom Officer | 59,420 0.08% of outstanding | $5.7M | Mar 24, 2026 | none |
| Mar 12, 2026 | HENRY E PELISH Officer | 38,197 0.05% of outstanding | $3.8M | Mar 12, 2026 | $502k |
| Mar 6, 2026 | James Richard Porter Officer | 90,000 0.12% of outstanding | $8.8M | Mar 6, 2026 | none |
| Feb 17, 2026 | Matthew Shair Director | 5,850 0.01% of outstanding | $589k | Feb 17, 2026 | $2.4M |
| Feb 17, 2026 | Matthew Shair Director | 1,650 0.00% of outstanding | $166k | Feb 17, 2026 | $2.4M |
| Jan 22, 2026 | DEBORAH MILLER Officer | 21,000 0.03% of outstanding | $2.3M | Jan 22, 2026 | $6.6M |
| Jan 5, 2026 | Alexandra Balcom Officer | 4,236 0.01% of outstanding | $412k | Jan 5, 2026 | $6.5M |
| Jan 5, 2026 | Deborah Ann Miller Officer | 4,363 0.01% of outstanding | $425k | Jan 5, 2026 | $8.8M |
| Jan 5, 2026 | Darlene Noci Officer | 4,236 0.01% of outstanding | $412k | Jan 5, 2026 | $1.2M |
| Jan 5, 2026 | James Richard Porter Officer, Director | 17,890 0.03% of outstanding | $1.7M | Jan 5, 2026 | $2.4M |
| Jan 5, 2026 | Christopher Durant Turner Officer | 4,236 0.01% of outstanding | $412k | Jan 5, 2026 | none |
| Jan 5, 2026 | Henry E. Pelish Officer | 2,496 0.00% of outstanding | $243k | Jan 5, 2026 | $2.2M |
| Dec 30, 2025 | Darlene Noci Officer | 15,000 0.02% of outstanding | $1.5M | Dec 30, 2025 | $846k |
| Dec 8, 2025 | Alexandra Balcom Officer | 7,084 0.01% of outstanding | $776k | Dec 8, 2025 | $9.1M |
| Nov 17, 2025 | Alexandra Balcom Officer | 13,854 0.02% of outstanding | $1.3M | Nov 17, 2025 | $7.7M |
| Nov 17, 2025 | DEBORAH MILLER Officer | 17,200 0.03% of outstanding | $1.7M | Nov 17, 2025 | $5.3M |
| Oct 30, 2025 | DEBORAH MILLER Officer | 22,800 0.03% of outstanding | $2.3M | Oct 30, 2025 | $3.0M |
| Oct 27, 2025 | Matthew Shair Director | 18,150 0.03% of outstanding | $1.8M | Oct 27, 2025 | none |
| Oct 27, 2025 | Matthew Shair Director | 64,350 0.10% of outstanding | $6.4M | Oct 27, 2025 | none |
Transactions
The newest 50 of 685 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Class A Common Stockindirect: Through Deerfield Private Design Fund IV, L.P. | -8,299,225 | $124.00 | $1.0B | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Class A Common Stockindirect: Through Deerfield Healthcare Innovations Fund, L.P. | -8,299,225 | $124.00 | $1.0B | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Class A Common Stockindirect: Through Deerfield Partners, L.P. | -650,000 | $124.00 | $81M | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | UTender of shares Class A Common Stockindirect: Through Deerfield Mangement Company, L.P. | -5,146 | $124.00 | $638k | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | UTender of shares Class A Common Stockindirect: Through Deerfield Mangement Company, L.P. | -5,146 | $124.00 | $638k | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Class A Common Stock - Restricted Stock Unitsindirect: Through Deerfield Mangement Company, L.P. | -3,444 | $124.00 | $427k | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Class B Common Stockderivativeindirect: Through Deerfield Private Design Fund IV, L.P. | -2,717,627 | $124.00 | $337M | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Class B Common Stockderivativeindirect: Through Deerfield Healthcare Innovations Fund, L.P. | -2,717,627 | $124.00 | $337M | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Stock Option (right to buy)derivativeindirect: Through Deerfield Mangement Company, L.P. | -43,000 | - | - | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Stock Option (right to buy)derivativeindirect: Through Deerfield Mangement Company, L.P. | -43,000 | - | - | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Stock Option (right to buy)derivativeindirect: Through Deerfield Mangement Company, L.P. | -20,000 | - | - | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Stock Option (right to buy)derivativeindirect: Through Deerfield Mangement Company, L.P. | -20,000 | - | - | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Stock Option (right to buy)derivativeindirect: Through Deerfield Mangement Company, L.P. | -15,000 | - | - | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Stock Option (right to buy)derivativeindirect: Through Deerfield Mangement Company, L.P. | -15,000 | - | - | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Stock Option (right to buy)derivativeindirect: Through Deerfield Mangement Company, L.P. | -3,789 | - | - | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Stock Option (right to buy)derivativeindirect: Through Deerfield Mangement Company, L.P. | -3,789 | - | - | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Stock Option (right to buy)derivativeindirect: Through Deerfield Mangement Company, L.P. | -4,147 | - | - | 0 | Jul 17, 2026 |
| Jul 15, 2026 | James E Flynn director, owner, other | DDisposition to issuer Stock Option (right to buy)derivativeindirect: Through Deerfield Mangement Company, L.P. | -4,147 | - | - | 0 | Jul 17, 2026 |
| Jul 15, 2026 | Benjamin Lane See Remarks | UTender of shares Class A Common Stock | -21,092 | $124.00 | $2.6M | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Henry E. Pelish Chief Scientific Officer | UTender of shares Class A Common Stock | -22,393 | $124.00 | $2.8M | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Anna Protopapas director | UTender of shares Class A Common Stock | -5,146 | $124.00 | $638k | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Darlene Noci Chief Development Officer | UTender of shares Class A Common Stock | -17,017 | $124.00 | $2.1M | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Grant C. Bogle director | UTender of shares Class A Common Stock | -3,714 | $124.00 | $461k | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Sapna Srivastava director | UTender of shares Class A Common Stock | -5,146 | $124.00 | $638k | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Alexandra Balcom Chief Financial Officer | UTender of shares Class A Common Stock | -44,433 | $124.00 | $5.5M | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Deborah Ann Miller Chief Legal Officer | UTender of shares Class A Common Stock | -18,534 | $124.00 | $2.3M | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Michael L. Meyers director | UTender of shares Class A Common Stock | -5,146 | $124.00 | $638k | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Cameron Wheeler director | UTender of shares Class A Common Stock | -5,146 | $124.00 | $638k | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Christy J. Oliger director | UTender of shares Class A Common Stock | -1,324 | $124.00 | $164k | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Christopher Durant Turner Chief Medical Officer | UTender of shares Class A Common Stock | -31,530 | $124.00 | $3.9M | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Ron Squarer director | DDisposition to issuer Class A Common Stock - Restricted Stock Units | -6,281 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | James Richard Porter President and CEO | UTender of shares Class A Common Stock | -203,529 | $124.00 | $25M | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Deborah Ann Miller Chief Legal Officer | DDisposition to issuer Class A Common Stock - Restricted Stock Units | -41,100 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Benjamin Lane See Remarks | DDisposition to issuer Class A Common Stock - Restricted Stock Units | -29,433 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Henry E. Pelish Chief Scientific Officer | DDisposition to issuer Class A Common Stock - Restricted Stock Units | -41,100 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Anna Protopapas director | DDisposition to issuer Class A Common Stock - Restricted Stock Units | -3,444 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Alexandra Balcom Chief Financial Officer | DDisposition to issuer Class A Common Stock - Restricted Stock Units | -41,100 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Cameron Wheeler director | DDisposition to issuer Class A Common Stock - Restricted Stock Units | -3,444 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Sapna Srivastava director | DDisposition to issuer Class A Common Stock - Restricted Stock Units | -3,444 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | James Richard Porter President and CEO | DDisposition to issuer Class A Common Stock - Restricted Stock Units | -121,350 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Michael L. Meyers director | DDisposition to issuer Class A Common Stock - Restricted Stock Units | -3,444 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Darlene Noci Chief Development Officer | DDisposition to issuer Class A Common Stock - Restricted Stock Units | -41,100 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Christy J. Oliger director | DDisposition to issuer Class A Common Stock - Restricted Stock Units | -6,091 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Ron Squarer director | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,418 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Grant C. Bogle director | DDisposition to issuer Class A Common Stock - Restricted Stock Units | -5,577 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Christopher Durant Turner Chief Medical Officer | DDisposition to issuer Class A Common Stock - Restricted Stock Units | -41,100 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | Benjamin Lane See Remarks | AGrant or award Class A Common Stock - Performance Stock Units | +7,120 | $0.00 | $0 | 7,120 | Jul 15, 2026 |
| Jul 15, 2026 | Deborah Ann Miller Chief Legal Officer | AGrant or award Class A Common Stock - Performance Stock Units | +14,350 | $0.00 | $0 | 14,350 | Jul 15, 2026 |
| Jul 15, 2026 | Darlene Noci Chief Development Officer | AGrant or award Class A Common Stock - Performance Stock Units | +14,350 | $0.00 | $0 | 14,350 | Jul 15, 2026 |
| Jul 15, 2026 | Michael L. Meyers director | DDisposition to issuer Stock Option (Right to Buy)derivative | -8,361 | - | - | 0 | Jul 15, 2026 |
50 of 685 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Alexandra BalcomChief Financial Officer
- Grant C. Bogledirector
- James E Flynnowner, director, other
- Benjamin LaneSee Remarks
- Michael L. Meyersdirector
- Deborah Ann MillerChief Legal Officer
- Darlene NociChief Development Officer
- Christy J. Oligerdirector
- Henry E. PelishChief Scientific Officer
- James Richard PorterPresident and CEO
- Anna Protopapasdirector
- Matthew Shairdirector
- Ron Squarerdirector
- Sapna Srivastavadirector
- Christopher Durant TurnerChief Medical Officer
- Cameron Wheelerdirector
Questions about NUVL
Answered from the filings on this page, as of the latest one.
Are insiders buying NUVL?
No. In the last 90 days no insider at Nuvalent, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade NUVL on the open market?
Henry E. Pelish (Chief Scientific Officer) sold $261k of NUVL on Jul 9, 2026 and filed the Form 4 on Jul 10, 2026. InsiderTell scored 23 (weak), under a 10b5-1 plan, with 4 insiders on the same side within 14 days.
How many insiders file Form 4 at Nuvalent, Inc.?
16 people have filed a Form 4 at Nuvalent, Inc., among them Alexandra Balcom (Chief Financial Officer), Grant C. Bogle (director), James E Flynn (10% owner and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.